Natural killer cells and cancer therapy, what we know and where we are going

被引：11

作者：

Ghaemdoust, Faezeh ^{[1
,2
]}

Keshavarz-Fathi, Mahsa ^{[1
,2
,3
]}

Rezaei, Nima ^{[3
,4
]}

机构：

[1] Univ Tehran Med Sci, Sch Med, Tehran 1416753955, Iran

[2] USERN, CIP, Tehran 1419733151, Iran

[3] Univ Tehran Med Sci, Childrens Med Ctr, Res Ctr Immunodeficiencies, Tehran 1419733151, Iran

[4] Univ Tehran Med Sci, Sch Med, Dept Immunol, Tehran 1416753955, Iran

来源：

IMMUNOTHERAPY | 2019年 / 11卷 / 14期

关键词：

adoptive immunotherapy; antibody therapy; antibody-dependent cellular cytotoxicity; cancer immunosurveillance; cancer immunotherapy; natural killer cells; RECOMBINANT HUMAN INTERLEUKIN-15; DEPENDENT CELLULAR CYTOTOXICITY; APOPTOSIS-INDUCING LIGAND; PHASE-1; CLINICAL-TRIAL; ACUTE MYELOID-LEUKEMIA; EX-VIVO EXPANSION; NK CELLS; ADOPTIVE TRANSFER; BREAST-CANCER; HLA-E;

D O I：

10.2217/imt-2019-0040

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Natural killer (NK) cells are among the significant components of innate immune system and they have come to the first line of defense against tumor cells developing inside the body. CD56lo/CD16(+) NK cells are highly cytotoxic and CD56hi NK cells can produce cytokines and perform a regulatory function. Specific features of NK cells have made them a unique choice for cancer immunotherapy. Simple interventions like cytokine-injection to boost the internal NK cells were the first trials to target these cells. Nowadays, many other types of intervention are under investigation, such as adoptive NK cell immunotherapy. In this paper, we will discuss the biology and function of NK cells in cancer immunosurveillance and therapeutic approaches against cancer via using NK cells.

引用

页码：1231 / 1251

页数：21

共 159 条

[1] Structural elucidation of the m157 mouse cytomegalovirus ligand for Ly49 natural killer cell receptors [J].

Adams, Erin J. ;

Juo, Z. Sean ;

Venook, Rayna Takaki ;

Boulanger, Martin J. ;

Arase, Hisashi ;

Garcia, K. Christopher .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (24) :10128-10133

[2] In situ delivery of allogeneic natural killer cell (NK) combined with Cetuximab in liver metastases of gastrointestinal carcinoma: A phase I clinical trial [J].

Adotevi, O. ;

Godet, Y. ;

Galaine, J. ;

Lakkis, Z. ;

Idirene, I. ;

Certoux, J. M. ;

Jary, M. ;

Loyon, R. ;

Laheurte, C. ;

Kim, S. ;

Dormoy, A. ;

Pouthier, F. ;

Barisien, C. ;

Fein, F. ;

Tiberghien, P. ;

Pivot, X. ;

Valmary-Degano, S. ;

Ferrand, C. ;

Morel, P. ;

Delabrousse, E. ;

Borg, C. .

ONCOIMMUNOLOGY, 2018, 7 (05)

[3] Escape from immunotherapy: possible mechanisms that influence tumor regression/progression [J].

Ahmad, M ;

Rees, RC ;

Ali, SA .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2004, 53 (10) :844-854

[4] Tetrameric complexes of human histocompatibility leukocyte antigen (HLA)-G bind to peripheral blood myelomonocytic cells [J].

Allan, DSJ ;

Colonna, M ;

Lanier, LL ;

Churakova, TD ;

Abrams, JS ;

Ellis, SA ;

McMichael, AJ ;

Braud, VM .

JOURNAL OF EXPERIMENTAL MEDICINE, 1999, 189 (07) :1149-1155

[5] Differential activation of cord blood and peripheral blood natural killer cells by cytokines [J].

Alnabhan, Rehab ;

Madrigal, Alejandro ;

Saudemont, Aurore .

CYTOTHERAPY, 2015, 17 (01) :73-85

[6] Advantages and clinical applications of natural killer cells in cancer immunotherapy [J].

Ames, Erik ;

Murphy, William J. .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2014, 63 (01) :21-28

[7] Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells [J].

Andre, Pascale ;

Denis, Caroline ;

Soulas, Caroline ;

Bourbon-Caillet, Clarisse ;

Lopez, Julie ;

Arnoux, Thomas ;

Blery, Mathieu ;

Bonnafous, Cecile ;

Gauthier, Laurent ;

Morel, Ariane ;

Rossi, Benjamin ;

Remark, Romain ;

Breso, Violette ;

Bonnet, Elodie ;

Habif, Guillaume ;

Guia, Sophie ;

Lalanne, Ana Ines ;

Hoffmann, Caroline ;

Lantz, Olivier ;

Fayette, Jerome ;

Boyer-Chammard, Agnes ;

Zerbib, Robert ;

Dodion, Pierre ;

Ghadially, Hormas ;

Jure-Kunkel, Maria ;

Morel, Yannis ;

Herbst, Ronald ;

Narni-Mancinelli, Emilie ;

Cohen, Roger B. ;

Vivier, Eric .

CELL, 2018, 175 (07) :1731-+

[8] Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial [J].

Arai, S. ;

Meagher, R. ;

Swearingen, M. ;

Myint, H. ;

Rich, E. ;

Martinson, J. ;

Klingemann, H. .

CYTOTHERAPY, 2008, 10 (06) :625-632

[9]

Arneson LN, 2005, NEUROIMMUNE, V5, P151, DOI 10.1016/S1567-7443(05)80014-6

[10] The biology of innate lymphoid cells [J].

Artis, David ;

Spits, Hergen .

NATURE, 2015, 517 (7534) :293-301

← 1 2 3 4 5 6 7 8 9 10 →